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Contribution of early rejection episodes to chronic rejection in a kidney
retransplantation model. Chronic graft rejection represents the single
most important risk factor for unsatisfactory long-term results after organ
transplantation. In addition to various alloantigen dependent and inde-
pendent factors, acute rejection episodes have been cited as a major
immunological risk factor. However, the effects of acute rejection epi-
sodes on long-term graft outcome remains unknown. To examine the
influence of a single early rejection event on ultimate graft outcome,
acutely rejecting rat kidney grafts were retransplanted sequentially into
syngeneic rats and their functional and structural behavior assessed over
time. LEWxBNF1 kidney allografts and LEW isografts were removed
from their LEW recipients after three, four, five and seven days (N 5
12/group/time period) and retransplanted into donor strain hosts. The
grafts were followed functionally and harvested four, eight, and 32 weeks
later. Urinary protein excretion was measured weekly. Kidneys were
examined morphologically and immunohistologically using monoclonal
antibodies (mAbs) against macrophages (ED-1), T cells and their subsets
(CD5, CD4, CD8), MHC class II expression (OX3) and adhesion mole-
cules (ICAM-1 and LFA-1a). The mean standard time 6 SD of non-
retransplanted allografts was 14.5 6 two days; isografts functioned indef-
initely. At five and seven days, acutely rejecting allografts showed massive
cellular infiltrates associated with extensive necrosis. These changes could
not be reversed by retransplantation and the syngeneic recipients later
died of renal failure. In contrast, most allografts retransplanted earlier in
the process recovered completely when retransplanted after three (12 of
12 allografts) and four (7 of 12 allografts) days. During the subsequent
follow-up period, urinary protein excretion was comparable in retrans-
planted allografts and isografts. The increased mononuclear cell infiltra-
tion in non-retransplanted allografts seen at three and four days was only
occasionally observed during the follow-up period after retransplantation.
Only a few sclerosed glomeruli (;15%), mild arterial changes and
minimal cellular infiltrates were observed by 32 weeks, which were similar
to that seen in retransplanted isografts. A single acute rejection episode
was completely reversible and did not progress to chronic rejection if
retransplanted into syngeneic donors when the inflammatory changes are
still early. Those results demonstrate the critical effect of alloantigen-
dependent events on chronic graft deterioration, and indicate that prompt
and aggressive treatment of initial acute rejection episodes are beneficial
to protect against late deleterious changes in the graft.
Although early results of clinical transplantation have improved
progressively, the ultimate goal of organ transplantation, which is
to provide long-term treatment for irreversible organ failure, has
not yet been achieved. Chronic rejection has been cited as the
most important cause of late graft loss [1–4]. Although the
functional and morphological findings are well characterized, the
pathophysiological mechanisms leading to graft deterioration
secondary to the evolution of this process are poorly understood.
Potential risk factors include alloantigen-dependent factors such
as early acute rejection [5–9] and HLA-matching [10], and
alloantigen-independent components including initial ischemia
and reperfusion injury, inadequate functional nephron mass, viral
infections and drug nephrotoxicity [2, 11–14]. These events may
affect the process either alone or in concert.
The influence of early acute rejection on long-term graft
function has been shown in several clinical series [5–8]. However,
the characteristics (morphological changes, time of occurrence
and success of treatment) of acute rejection episodes, including
mechanisms resulting in long-term graft dysfunction, remain
unknown. Two explanations have been offered for this relation-
ship: first, alloreactivity may persist despite putatively satisfactory
maintenance immunosuppression. As a consequence, indirect
presentation of donor MHC peptides may become increasingly
important over time [15]. Secondly, predominantly alloantigen-
independent events may gain influence over the long term. The
ongoing immunological injury caused by repeated subclinical
acute rejection episodes may additionally lead to progressive
reduction of functioning organ mass, causing hyperfunction of the
remaining nephron units which themselves gradually fibrose over
time. The influence of reduced organ mass on long-term function
has been demonstrated in several experimental and clinical set-
tings [3, 13, 16].
Previous experimental studies demonstrated that early acute
rejection episodes are reversible by retransplantation back into a
donor strain animal. However, those experiments did not follow
retransplanted grafts long-term [17–19]. Thus, it remains un-
known if the severity of acute rejection and the subsequent
damage to the graft may contribute to chronic graft failure even in
the absence of an ongoing immunological stimulus. Complete
reversal of acute rejection by syngeneic retransplantation in the
absence of the development of chronic graft deterioration may
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support the critical role of alloantigen-dependent effects during
the process and the concept to treat acute rejection episodes early
and aggressively.
We attempted to examine the contribution of a single acute
rejection episode on the development of long-term graft changes
by sequential retransplantation of acutely rejected rat renal
allografts into donor strain recipients, and studied their changes in
a long-term follow-up.
METHODS
The model
Male inbred 200 to 250 g rats (Charles River, Sulzbach,
Germany), were used throughout the experiments. Lewis Brown
Norway F1 (LEWxBNF1,RT
1/n) kidney allografts were grafted
into Lewis (LEW, RT11) recipients using standard microsurgical
techniques; LEW kidneys placed in LEW rats served as isograft
controls. Grafts were transplanted orthotopically to recipient
renal vessels and ureter by end-to-end anastomosis using 10-0
prolene. Both native kidneys were removed during transplanta-
tion in all experimental groups. Graft tissues were harvested after
three, four, five, and seven days (N 5 5 allografts, N 5 3
isografts/time interval). Survival times of unmodified allograft
recipients was tested in a separate group (N 5 6).
Allografted and isografted kidneys from a parallel series of
recipients were retransplanted into bilaterally nephrectomized
donor strain rats (LEWxBNF1 or LEW, respectively) three, four,
five and seven days after their initial engraftment (N 5 12
allografts, N 5 3 isografts/time interval). Operative technique and
duration of ischemic time (;30 min) were similar to the first
transplants. Retransplanted grafts were harvested after four,
eight, and 32 weeks. Native and uninephrectomized LEW and
LEWxBNF1 controls were examined in parallel throughout the
observation period. All kidneys were assessed serially for function,
morphology and immunohistology.
Functional studies
Urine samples (24 hr) were collected serially at two week
intervals. Protein excretion was measured by precipitation with
20% CCl3COOH. Turbidity was assessed at a wavelength of 415
nm using a Hitachi 911 analyzer.
Histology
Kidneys were removed at serial intervals in experimental and
control groups and fixed in 5% buffered formalin. Paraffin
sections were stained with hematoxylin and eosin, periodic acid-
Schiff, Trichrome and Silver-Mason, and assessed by light micros-
copy. To determine the extent of glomerulosclerosis, . 100
glomeruli/kidney were counted and the ratio of sclerosed glomer-
uli/total glomeruli expressed as a percentage.
Immunohistology
Portions of representative kidneys in experimental and control
grafts were snap frozen in liquid nitrogen, cut (4 mm), fixed in
acetone for 10 minutes, air dried and stained with mouse mono-
clonal antibodies (mAbs) to CD51 T-cells (OX-19), CD41 T
helper cells (W3/25), CD81 T cytotoxic/suppressor cells (OX-8),
macrophages (ED-1), MHC class II (OX3; Serotec, Wiesbaden,
Germany), intercellular adhesion molecule 1 (ICAM-1) and lym-
phocyte function-associated antigen 1a (LFA-1a; both Genzyme,
Wiesbaden, Germany). After specific mAb staining, the sections
were then interacted with rabbit anti-mouse IgG following a
mouse anti-alkaline phosphatase complex (APAAP), and the
sections were then counterstained with hematoxylin. MHC class II
and ICAM-1 expression was quantified on a 0 to 41 scale (41 5
dense); positive cell counts were expressed as mean 6 SD of
cells/field of view (c/FV); . 20 FV/section were evaluated at
3400.
Statistics
Statistical significance was ascertained using ANOVA and the
Student’s t-test.
RESULTS
Survival data
Allograft recipients (N 5 6) died of renal failure 14.5 6 two
days (mean 6 SD) after transplantation while isografted hosts
survived indefinitely.
The majority of allograft recipients (23 of 24 animals) that were
retransplanted five and seven days after the original kidney
engraftment, a period when graft destruction was far advanced,
died 3 6 1 days later; only one animal that had been retrans-
planted after five days survived for 28 days. However, if retrans-
plantation was performed earlier in the course of the process,
most allograft recipients recovered completely (12 of 12 and 7 of
12 retransplanted after 3 and 4 days, respectively). Several (5 of
12) kidney allografts retransplanted four days after their initial
engraftment failed after two to three weeks, having sustained their
recipients during that period before deteriorating completely,
which suggests that these animals sustained progressive ongoing
and irreversible injury (Fig. 1). All recipients of retransplanted
isografts (N 5 12) survived indefinitely.
Function
Urinary protein excretion in non-retransplanted control al-
lografted hosts peaked by 11 days (86 6 10 mg/24 hr), diminishing
rapidly thereafter as the grafts failed and animals began to die of
renal failure a few days later.
Allografts retransplanted after seven days never regained func-
tion and remained anuric. Those retransplanted at five days also
never recovered, with the exception of the single animal who died
with progressive proteinuria (162 mg/24 hr) at 28 days.
Allograft function returned to stable values after retransplan-
tation at three and four days, which was similar to retransplanted
isograft recipients or uninephrectomized native controls. How-
ever, proteinuria increased slightly in retransplanted allografts
(23 6 5 mg/24 hr and 28 6 7 mg/24 hr by days 3 and 4), isografts
(42 6 11 mg/24 hr) and native uninephrectomized controls (26 6
6 mg/24 hr; P 5 NS) by 32 weeks, and was increased as compared
to native non-nephrectomized controls (12 6 3 mg/24 hr, P ,
0.05) presumably as a consequence of ischemic injury and reduc-
tion of functioning kidney mass. The five allograft recipients
eventually dying after retransplantation four days after the initial
engraftment demonstrated progressive proteinuria at 18 6 3 days
(146 6 12 mg/24 hr; Fig. 2).
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Morphology
Progressive alterations were observed in the non-retransplanted
allografted kidneys. By three days mononuclear cells were scat-
tered around vessels and tubules, and by four days the numbers of
infiltrating cells had increased. Cellular infiltration peaked by five
days, which declined slightly by seven days. Associated structural
changes developing during the later stages of acute rejection
included interstitial inflammation, loss of tubules, endothelialitis,
and finally, as the animals exhibited renal failure, increasing areas
of edema and necrosis.
The events of acute rejection occurring by five and seven days
could not be reversed by retransplantation. Most of the recipients
(23 of 24) died shortly thereafter with extensive and continuing
graft destruction. In contrast, in those allografts that recovered
completely after retransplantation at three and four days, only a
few mononuclear cells were observed around tubules and vessels
at 32 weeks, glomerulosclerosis remained minor (15%), and
arteries showed smooth muscle cell proliferation only occasion-
ally. Morphological changes characteristic of chronic rejection
were not observed. The allografts of the five animals that did not
recover completely after retransplantation at four days demon-
strated major cellular infiltrates, and loss of tubules with extensive
areas of necrosis when examined after two to three weeks.
Regrafted isograft controls showed normal morphology with
few mononuclear cells in the interstitium and around tubules.
However, by 32 weeks few cellular infiltrates with minor glomeru-
losclerotic and arteriosclerotic changes were observed, similar to
that in allografts recovering after retransplantation by three and
four days. Native kidneys in uninephrectomized animals remained
normal throughout the observation period (Fig. 3).
Immunohistology
Monocyte/macrophages and T-lymphocytes infiltrated allo-
grafts increasingly within three and four days after transplantation
Fig. 1. Survival data of allografts
retransplanted after 3, 4, 5, and 7 days are
shown. While all animals retransplanted after
three days survived indefinitely, most grafts (7
of 12) retransplanted after four days survived
the observation period. Animals never
recovered when retransplantation was
performed after 5 and 7 days.
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Fig. 2. Urinary protein excretion in allografts
retransplanted three (f) and four (F) days
after initial engraftment, retransplanted
isografts (l), uninephrectomized (), and
untreated native controls () are shown.
Proteinuria did not increase significantly in
experimental groups as compared to naive
uninephrectomized controls. However, a minor
increase was observed compared to non-
nephrectomized native controls by 32 weeks
(P , 0.05).
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(ED-1, 12 6 6 and 18 6 5 c/FV; CD-4, 10 6 5 and 18 6 7 c/FV;
CD-8, 15 6 4 and 19 6 8 c/FV, respectively; P 5 NS; LFA-1a,
16 6 4 and 18 6 6 c/FV, respectively). MHC class II expression
(31) was found on infiltrating and endothelial cells, and ICAM-1
was strongly expressed on vascular cells and in the interstitium
(31, days 3 and 4). Few mononuclear cell infiltrated isografts
were harvested after three and four days (ED-1, 4 6 2 and 3 6 1
c/FV; CD-4, 5 6 2 and 6 6 4 c/FV; CD-8, 3 6 2 and 2 6 2 c/FV,
respectively; P , 0.05), while few cells in the interstitium and
around vessels stained for LFA-1a (4 6 2 and 3 6 1 c/FV,
respectively, P , 0.05). Vascular endothelium and interstitial cells
stained for MHC II and ICAM-1 (21 and 31, respectively, P 5
NS).
By five days, allografts demonstrated peak cellular infiltrates
with slightly declining numbers by seven days (ED-1, 54 6 7 and
42 6 6 c/FV; CD-4, 28 6 4 and 20 6 6 c/FV; CD-8, 42 6 8 and
36 6 5 c/FV, respectively). LFA-1a (13 6 4 and 5 6 2 c/FV,
respectively; P , 0.01 vs. allografts by 3 and 4 days) and MHC II
expression (31) were found on infiltrating cells, in the intersti-
tium, on glomeruli and around vessels. ICAM-1 was expressed on
tubules, vascular endothelial cells and additionally on glomeruli,
(3 to 41 and 31, days 5 and 7, respectively). These changes,
associated with the major structural changes, could not be re-
versed by retransplantation. The immunohistological changes
observed in the retransplanted allografts were comparable despite
absence of the continuing host immunological challenge.
When allografts were retransplanted after 3 and 4 days and
harvested 4, 8 and 32 weeks later, the widespread cellular
infiltrates decreased in number, as grafts examined at 32 weeks
showed (ED-1, 6 6 3 and 8 6 2 c/FV; CD-4, 8 6 3 and 11 6 4
c/FV; CD-8, 6 6 3 and 5 6 2 c/FV, respectively; P , 0.01 vs.
non-retransplanted allografts at 3 and 4 days). Few interstitial
cells and glomeruli stained for ICAM-1 (21). MHC II expression
(21) and few LFA1 cells (4 6 2 and 6 6 3 c/FV, P , 0.01) were
found on cells in the interstitium and glomeruli. Of the five
animals retransplanted on day 4 and dying of renal failure two to
three weeks later, the allografts continued to demonstrate major
cellular infiltration (ED-1, 55 6 8 c/FV; CD-4, 36 6 9 c/FV; CD-8,
42 6 5 c/FV; P , 0.01 vs. non-retransplanted allografts on day 4;
P , 0.01 vs. allografts retransplanted by day 4 evaluated 32 weeks
later) with strong expression of ICAM-1 and MHC II (3 to 41 and
31, respectively) on infiltrating cells, around tubules and in
glomeruli.
Few cells (ED-1, 3 6 1 c/FV; CD-4, 4 6 2 c/FV; CD-8, 1 6 1
c/FV) were observed in isograft controls by 32 weeks, while only
occasional glomeruli and interstitial cells stained for ICAM-1 and
MHC class II [21]. Retransplantated isografts also demonstrated
minor cellular infiltrates 32 weeks after retransplantation (ED-1,
7 6 2 c/FV; CD-4, 8 6 4 c/FV; CD-8, 2 6 1 c/FV; P 5 NS vs.
retransplanted allografts retransplanted by days 3 and 4) regard-
less of the time of the second engraftment. Similarly, low grade
expression of ICAM-1 (1 to 21) and OX-3 (21) was found
around tubules and in glomeruli (Fig. 4).
DISCUSSION
Chronic graft rejection represents a major cause of attrition of
organ transplants over time. Although the pathophysiology of this
process is only incompletely understood, putative alloantigen-
dependent and -independent risk factors include acute and sub-
acute rejection episodes [5–7], initial ischemia and reperfusion
injury [11–14], organs from marginal donors, and reduced func-
tioning renal mass [4, 16], viral infections [20, 21] and drug toxicity
[22, 23]. Acute rejection episodes seem to be critical. In one
clinical report, for instance, cadaver kidney recipients never
experiencing acute rejection demonstrated a five-year survival
rate of 92% compared to 45% in recipients who had undergone at
least one rejection episode. Other studies have been confirmatory
[5–7].
To further study the contribution of acute rejection episodes on
chronic graft rejection, we retransplanted acutely rejecting rat
renal allografts sequentially into donor strain animals to remove
the ongoing host immunological drive. When retransplantation
was performed at early stages of the rejection process (days 3 and
4) most grafts recovered completely and did not progress to
chronic graft failure. Progressive deterioration in some animals by
four days was irreversible after retransplantation. Both the con-
cept of an already advanced acute rejection process and the
synergistic action of alloantigen dependent and independent
events (damage by ischemia and reperfusion injury) seem to be
plausible explanations. Further studies into those events are
currently being performed. The low grade cellular infiltration and
the development of minor signs of glomerulosclerosis observed
both in retransplanted allografts and isografts (3 and 4 days) over
the long-term probably were an expression of ischemic damage
and reperfusion injury during engraftment [13]. When the injury
was advanced (days 5 and 7) it could not be reversed by
retransplantation, and the recipients began to die shortly there-
after of kidney failure from progressive destruction.
Although differing from the clinical situation, no immunosup-
pressive treatment was used in our experimental acute rejection
model, as we attempted to emphasize the reversal of acute
rejection episodes and long-term outcome in the absence of a host
Fig. 3. Photomicrographs (magnification 3600) of hematoxylin and eosin stained renal allografts and isografts are shown. While the left column
represents isografts (A; LEW3LEW by three days) and acutely rejected renal allografts of the LEWxBNF13LEW model at progressive stages of the
rejection process (B, day 3; C, day 4; D, day 5; E, day 7), the right column represents retranplanted iso- and allografts, respectively (F, isograft
retansplanted by three days and evaluated after 32 weeks; G and H, allografts retransplanted after 3 and 4 days, respectively, and harvested 32 weeks
later). (I) A retransplanted allograft by day 5, evaluated when the animal died of renal failure after 28 days. (J) Allograft retransplanted by seven days
and dying two days later. Isografts demonstrated a normal morphology during the observation period with rare cellular infiltrates. Retransplanted
isografts (F) showed minor glomerulosclerotic and arteriosclerotic changes with few infiltrating MNC 32 weeks after retransplantation. Mononuclear
cell infiltrates increased progressively in allografts from days 3 to 4 (B, C), while allografts retransplanted after those time intervals and evaluated 32
weeks later (G and H) demonstrated only minor changes similar to retransplanted isografts (F). Cellular infiltrates were stronger in allografts
retransplanted by day 4, and the minor structural changes were comparable to those in retransplanted isografts and allografts retransplanted by day 3.
On the contrary, animals retransplanted 5 and 7 days after the original transplantation never recovered completely and died of renal failure shortly
thereafter. Major cellular infiltrates with extensive areas of necrosis present prior to retransplantation by 5 and 7 days (D, E) never recovered, as the
animals died of renal failure after syngeneic retransplantation (I and J).
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immunological drive. In addition, our model did not directly
correlate to clinical situations, as retransplantation removes the
ongoing allogeneic drive completely. The potential contribution
of a graft-versus-host reaction was not studied in our model.
However, similar changes in retransplanted allografts and
isografts seem to exclude ‘passenger’ LEW cells as influential
after retransplantation.
Analyzing such factors as the relationship between the time of
the occurrence of acute and chronic rejection, morphological
characteristics, severity and success of treatment seems to be
important [7–9]. It has been noted that early vascular rejection
resulted in a significantly decreased one- and five-year graft
survival rate, while patients experiencing an interstitial process or
no rejection showed comparable short- and long-term graft
function [7]. It seems particularly interesting to find in our
experimental studies that effectively treated early acute rejection
episodes (, 3 months) did not affect the rate of development of
chronic graft failure, while late acute episodes were highly influ-
ential on long-term graft outcome. Those latter observations may
also reflect a delayed diagnosis or more advanced stages of renal
failure secondary to inadequate follow-up [10, 11]. In addition, as
characteristics of cellular infiltrates varied during early and late
acute rejection episodes different mechanisms might apply [21].
Several reports associated frequent and early acute rejection
episodes with a poor long-term outcome [5–8, 24–26]. When
HLA-identical renal grafts were analyzed over the long-term,
chronic rejection rarely was noted, despite a high incidence of
early acute rejection episodes successfully reversed by pulse
steroid treatment [27]. Evaluating the association between acute
and chronic rejection, we suggest that the impairment seen after
the initial treatment was adversely related to long-term function,
while acute rejection episodes that were completely reversed had
no impact on the development of chronic graft dysfunction [28].
Although retransplantation experiments have been performed
before in transplantation settings, the impact of initial acute
rejection events has not been studied over the long-term [17–19,
29, 30]. Early stages of acute rejection [17–19] could be obviated
by replacement of the graft into donor strain animals; however, no
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Fig. 4. Quantitated immunohistologial findings for isografts harvested after 3 and 4 days (ITxd3, ITxd4), retransplanted isografts (IReTx,
retransplanted by day 3 and evaluated 32 weeks later), non-retransplanted allografts by 3, 4, 5 and 7 days (ATx d3 - d7) and retransplanted allografts
(AReTx d3 - d5, *retransplanted allografts by days 4 and 5 dying 2 to 4 weeks after retransplantation) are shown. Cell counts are quantitated as
cells/field of view and expressed as mean 6 SD; MHC and ICAM-1 are quantitated on a 0 to 41 scale. Cellular infiltrates were significantly different
between non-retransplanted allografts and isografts by 3 and 4 days (P , 0.05) and between allografts by 4 and 5 days (P , 0.01); no significant
differences were found between allografts retransplanted by 3 and 4 days and retransplanted isografts evaluated 32 weeks later. In addition, no
significant differences were observed for the expression of MHC II and ICAM-1 in any of the experimental groups. However, during the early phase
of the acute rejection process episode (days 3 and 4) MHC II and ICAM-1 were found predominantly on endothelial cells and in the interstitium, while
an additional glomerular expression has been observed during later stages (day 5) and in retransplanted allografts and isografts. (A) CD31 T cells; (B)
CD81 T cells; (C) LFA-a; (D) ED-1 1 monocytes/macrophages; (E) ICAM-1; (F) MHC class II.
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long-term follow-up has been reported after successful reversal of
acute rejection, with the exception of one early report that
described thickening of arterial walls in a dog kidney graft one
month after retransplantation [19]. Retransplantation experi-
ments in chronic rejection models have been studied before by us
and others [29, 30]. Graft coronary arteriosclerosis did not
develop when rat hearts were retransplanted back into a donor
strain animal within three days. However, when the same proce-
dure was performed later (. 3 days), graft vasculopathy eventu-
ally developed [30]. When heart allografts were retransplanted
into an animal of donor origin at early (14 days) and late stages
(50 days), mononuclear infiltration but not myointimal prolifera-
tion were reversed [31]. Retransplantation experiments in a
chronic kidney graft model demonstrated complete reversal of
functional and morphological changes if sclerosis had not become
too advanced [29]. Rat strain and treatment differences including
duration of ischemia and preservation techniques in the systems
used may explain these discrepancies. Although progressive
mononuclear cell infiltrates were present in the early stages of the
present acute model, retransplantation could remove the inflam-
matory process and the graft did not progress to chronic changes.
On the other hand, the already advanced acute condition re-
mained irreversible after retransplantation.
Minor cellular infiltrates were noted in both retransplanted
allografts and isografts, while minor glomerulosclerosis occurred
over time. The development of characteristic findings of chronic
graft dysfunction similar to those occurring in allografts at earlier
stages has been shown in clinical and experimental studies in
isografts, although generally at a period later than 32 weeks [32,
13]. Alloantigen-independent factors such as ischemia and reper-
fusion injury and their interaction with alloantigen-dependent
factors may be of particular importance in this context and need
further study. These factors may explain the sustained, slightly
elevated levels of proteinuria noted in these experiments.
In summary, we found that early acute rejection episodes were
completely reversible after syngeneic retransplantation and did
not lead to chronic progression of renal disease. Retransplanta-
tion at more advanced stages of acute rejection were irreversible.
Those observations demonstrate the critical contribution of al-
loresponsiveness on the development of chronic graft deteriora-
tion, and indicate that prompt and sufficient treatment of acute
rejection episodes may improve long-term graft outcome and
ameliorate synergistic events of alloantigen dependent and inde-
pendent events.
While several clinical studies have associated delayed graft
function with increased acute rejection episodes [31, 33], it has to
be determinated whether an additional ischemic at more ad-
vanced stages of the rejection process may support the concept of
a synergistic action of alloantigen dependent and independent
events.
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APPENDIX
LEW, Lewis rat strain; LEWxBNF1,RT
l/n, Lewis Brown Norway F1 rat
strain; mAb, monoclonal antibody; OX-19, CD51 T-cells; W3/25, CD41
T helper cells; OX-8, CD81 T cytotoxic/suppressor cells; ED-1, macro-
phages; OX-3, MHC class II; ICAM-1, intercellular adhesion molecule 1;
LFA-1a, lymphocyte function-associated antigen 1a; APAAP, anti-alka-
line phosphatase complex; c/FV, cells per field of view.
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